The Food and Drug Administration has approved Nasacort AQ Nasal Spray for children aged 2 to 5 for treating nasal symptoms of seasonal and perennial allergies, maker Sanofi-Aventis said.

Find patient medical information for Triamcinolone nasal on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Nasacort Allergy 24HR is labeled for use in children aged 2 years or older, adolescents, and adults. Nasacort Allergy 24HR should not be used in children aged under 2 years.

Chattem anticipates that Nasacort Allergy 24hr nasal spray will be available in Spring 2014. For more information call (423) 821-4571 or visit Nasacort.com . Related News ...

Sanofi-aventis's Nasacort AQ (triamcinolone acetonide nasal spray) has been approved for the treatment of seasonal and perennial allergic rhinitis in children 2-5 years of age.

WASHINGTON The Food and Drug Administration has approved a drug for treating seasonal and perennial allergies in children aged 2 to 5.. The drug, Sanofi-Aventis Nasacort AQ, received approval for ...

The study showed that Nasacort AQ, given as 1 spray/nostril once daily for four weeks to children aged 2-5 years, with year-round allergic rhinitis diagnosed for at least one year, significantly ...

A battle for kids' pollen proclivities is shaping up this allergy season. Both Sanofi's Nasacort and GlaxoSmithKline's Flonase have introduced children's-labeled versions of the now-OTC steroid ...

Sanofi-aventis announced today the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2-5 years old for the treatment .

A new allergy drug for children will soon be on the market: The FDA has approved Sanofi-Aventis' Nasacort for children between the ages of 2 and 5 years old for the treatment of allergies. The FDA ...

A post-marketing study of 299 children ages 3 to 9 showed a 0.45 cm/year drop in growth velocity at 1 year in those taking the drug compared with a placebo group (95% CI: 0.78-0.11%).

A local doctor caused a stir at an open hearing at the Food and Drug Administration about the switch of prescription allergy drug Nasacort AQ to over-the-counter.